title: In vivo high intrinsic efficacy of triazolam: a positron emission tomography study in nonhuman primates.
abstract: The triazolobenzodiazepine triazolam is a central-type benzodiazepine receptor (BZR) ligand that is widely prescribed as a hypnotic agent. Triazolam produces its effects through potentiation of gamma-aminobutyric acid-mediated neurotransmission. Findings reported from in vitro binding studies showed some discrepancies concerning the pharmacological characteristics of triazolam. The present study aims to characterize in vivo the biochemical properties of triazolam, i.e., cerebral pharmacokinetics, interaction with BZR, potency, and intrinsic efficacy. Triazolam was studied in living nonhuman primates using positron emission tomography. Two different studies were carried out: (a) a direct study using [11C]triazolam and (b) an indirect competition study using the radiolabeled BZR antagonist 1C]flumazenil. Results showed that, in the brain in vivo, triazolam binds specifically and competitively to the BZR. Its rapid cerebral kinetics is consistent with a hypnotic profile (maximal binding after 23 min, elimination half-life of 202 min). Triazolam is very potent in displacing [11C]flumazenil (ID50 = 28 +/- 6 micrograms/kg). Hill analysis of the displacement curve does not show obvious binding-site heterogeneity. Triazolam is 20 times more potent in displacing [11C]flumazenil and 50 times more potent in inhibiting pentylenetetrazol-induced paroxysmal activity than the full benzodiazepine agonist diazepam. Interestingly, the simultaneous use of positron emission tomography and EEG recording allowed us to show that triazolam-positive intrinsic efficacy is slightly higher (20%) than that of diazepam. An attractive hypothesis proposes that the severity of side effects of BZR ligands is proportional to their intrinsic efficacy. Therefore, our study shows that triazolam side effects, as for other benzodiazepines, may be related to its high intrinsic efficacy in vivo.
authors.affiliation: Service Hospitalier Frédéric Joliot, CNRS URA 1285, CEA, DSV, Orsay, France.
authors.forename: M
authors.initials: M
authors.lastname: Bottlaender
authors.forename: E
authors.initials: E
authors.lastname: Brouillet
authors.forename: M
authors.initials: M
authors.lastname: Varastet
authors.forename: C
authors.initials: C
authors.lastname: Le Breton
authors.forename: L
authors.initials: L
authors.lastname: Schmid
authors.forename: C
authors.initials: C
authors.lastname: Fuseau
authors.forename: R
authors.initials: R
authors.lastname: Sitbon
authors.forename: C
authors.initials: C
authors.lastname: Crouzel
authors.forename: M
authors.initials: M
authors.lastname: Mazière
mesh_terms: D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology*; D001769:Blood / Q000378:metabolism; D001921:Brain / Q000000981:diagnostic imaging / Q000378:metabolism*; D005442:Flumazenil / Q000378:metabolism; D008024:Ligands; D008297:Male; D010215:Papio; D011963:Receptors, GABA-A / Q000378:metabolism; D014055:Tomography, Emission-Computed; D014229:Triazolam / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology*
chemical_list: D000927:Anticonvulsants; D008024:Ligands; D011963:Receptors, GABA-A; D014229:Triazolam; D005442:Flumazenil